Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

6-Weeks of Blood Flow Restriction Training on Immune Cell Function and Bioenergetics

23 juni 2026 uppdaterad av: Jonathan Little, University of British Columbia

Impact of 6-Weeks of Blood Flow Restriction Training on Immune Cell Function and Bioenergetics in Adults withT2D

To conduct a randomized control trial to determine the impact of 6-weeks of blood flow restriction training on immune cell function and bioenergetics in adults living with type 2 diabetes.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Participants will be randomized to a regular treadmill walking group or treadmill walking with blood flow restriction (BFR) group for 6 weeks. In both groups participants will complete treadmill walking on 3 days per week for 6 weeks. During week 1 participants will walk for 21 minutes during each session which will be increased to 32 minutes for the remaining 5 weeks of the study. In both groups the treadmill speed and grade will be set to elicit 40-50% heart rate reserve. In the BFR group the cuffs will be inflated based on each participants individualized limb occlusion pressure (LOP). The cuffs will remain inflated for the entire session but will deflate for 1 minute every 10 minutes based on safety recommendations. The percentage of LOP will progressively increase over the course of the intervention. Weeks 1 and 2 will be completed at 60% LOP, after which pressure will increase by 5% each subsequent week, corresponding to 65%, 70%, 75%, and 80% LOP during weeks 3, 4, 5, and 6, respectively. All outcomes will be assessed at baseline before randomization and at the end of the 6-week intervention.

Studietyp

Interventionell

Inskrivning (Beräknad)

20

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • British Columbia
      • Kelowna, British Columbia, Kanada, V1V 1V7
        • Rekrytering
        • University of British Columbia Okanagan
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

A. Aged 19-64 years. B. Diagnosed with type 2 diabetes with current HbA1c 5.7-9.0% C. Completing <150 minutes of moderate-vigorous physical activity per week.

Exclusion Criteria:

A. Chronic musculoskeletal condition or recent (within 2 years) cardiovascular event preventing participation in exercise.

B. Unstable type 2 diabetes medication of the last 3 months C. Absolute contraindications to BFR (i.e., peripheral vascular disease) D. A self-reported diagnosis of low iron concentrations, anemia, or being treated for these conditions E. A diagnosis of any red blood cell-altering condition (i.e., sickle cell anemia, poikilocytosis) F. Currently living with any cardiovascular disease, which would impact the ability to participate in exercise safely G. Currently prescribed any medication which would impact the ability to use a heart rate monitor to accurately track intensity

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Grundläggande vetenskap
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Treadmill walking with blood flow restriction
Treadmill walking with blood flow restriction performed 3 days per week for 6 weeks.
In both groups participants will complete treadmill walking on 3 days per week for 6 weeks. During the first week participants will walk continuously for 21 minutes during each training session which will be increased to 32 minutes per training session for weeks 2-6. In both groups the treadmill speed and grade will be set to elicit 40-50% heart rate reserve. In the BFR group the cuffs will be inflated based on each participants individualized limb occlusion pressure (LOP). The cuffs will remain inflated for the entire session but will deflate for 1 min every 10 min based on safety recommendations. The percentage of LOP will progressively increase over the course of the intervention. Weeks 1 and 2 will be completed at 60% LOP, after which pressure will increase by 5% each subsequent week, corresponding to 65%, 70%, 75%, and 80% LOP during weeks 3, 4, 5, and 6, respectively.
Aktiv komparator: Treadmill Walking
Treadmill walking performed 3 days per week for 6 weeks.
In both groups participants will complete treadmill walking on 3 days per week for 6 weeks. During the first week participants will walk continuously for 21 minutes during each training session which will be increased to 32 minutes per training session for weeks 2-6. In both groups the treadmill speed and grade will be set to elicit 40-50% heart rate reserve. In the BFR group the cuffs will be inflated based on each participants individualized limb occlusion pressure (LOP). The cuffs will remain inflated for the entire session but will deflate for 1 min every 10 min based on safety recommendations. The percentage of LOP will progressively increase over the course of the intervention. Weeks 1 and 2 will be completed at 60% LOP, after which pressure will increase by 5% each subsequent week, corresponding to 65%, 70%, 75%, and 80% LOP during weeks 3, 4, 5, and 6, respectively.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in T-cell oxygen consumption rate (OCR) measured before and after the 6-week intervention
Tidsram: 0-6 weeks
T-cell OCR will be measured using a Seahorse Analyzer at baseline and after the 6-week intervention.
0-6 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in CD4 expression before and after the 6-week intervention
Tidsram: 0-6 weeks
The CD4 expression will be measured using flow cytometry at baseline and after the 6-week intervention.
0-6 weeks
Change in CD8 expression before and after the 6-week intervention
Tidsram: The CD8 expression will be measured using flow cytometry at baseline and after the 6-week intervention.
0-6 weeks
The CD8 expression will be measured using flow cytometry at baseline and after the 6-week intervention.
Change in % of T regulatory cells before and after the 6-week intervention
Tidsram: 0-6 weeks
The % T regulatory cells will be measured using flow cytometry at baseline and after the 6-week intervention.
0-6 weeks
Change in % of Th1 cells before and after the 6-week intervention
Tidsram: 0-6 weeks
The % Th1 cells will be measured using flow cytometry at baseline and after the 6-week intervention.
0-6 weeks
Change in % of Th2 cells before and after the 6-week intervention
Tidsram: The % Th2 cells will be measured using flow cytometry at baseline and after the 6-week intervention.
0-6 weeks
The % Th2 cells will be measured using flow cytometry at baseline and after the 6-week intervention.
Change in % of Th17 cells before and after the 6-week intervention
Tidsram: 0-6 weeks
The % Th17 cells will be measured using flow cytometry at baseline and after the 6-week intervention.
0-6 weeks
Change in CD66b+ expression before and after the 6-week intervention
Tidsram: The CD66b+ expression will be measured using flow cytometry at baseline and after the 6-week intervention.
0-6 weeks
The CD66b+ expression will be measured using flow cytometry at baseline and after the 6-week intervention.
Change in CD11b+ expression before and after the 6-week intervention
Tidsram: The CD11b+ expression will be measured using flow cytometry at baseline and after the 6-week intervention.
0-6 weeks
The CD11b+ expression will be measured using flow cytometry at baseline and after the 6-week intervention.
Change in CD63+ expression before and after the 6-week intervention
Tidsram: 0-6 weeks
The CD63+ expression will be measured using flow cytometry at baseline and after the 6-week intervention.
0-6 weeks
Change in % of classical monocytes before and after the 6-week intervention
Tidsram: 0-6 weeks
The % of classical monocytes will be measured using flow cytometry at baseline and after the 6-week intervention.
0-6 weeks
Change in % of intermediate monocytes before and after the 6-week intervention
Tidsram: 0-6 weeks
The % of intermediate monocytes will be measured using flow cytometry at baseline and after the 6-week intervention.
0-6 weeks
Change in % of non-classical monocytes before and after the 6-week intervention
Tidsram: 0-6 weeks
The % of non-classical monocytes will be measured using flow cytometry at baseline and after the 6-week intervention.
0-6 weeks
Change in TLR-4 expression on classical monocytes before and after the 6-week intervention
Tidsram: 0-6 weeks
The TLR-4 expression on classical monocytes will be measured using flow cytometry at baseline and after the 6-week intervention.
0-6 weeks
Change in TLR-4 expression on intermediate monocytes before and after the 6-week intervention
Tidsram: 0-6 weeks
The TLR-4 expression on intermediate monocytes will be measured using flow cytometry at baseline and after the 6-week intervention.
0-6 weeks
Change in TLR-4 expression on non-classical monocytes before and after the 6-week intervention
Tidsram: 0-6 weeks
The TLR-4 expression on non-classical monocytes will be measured using flow cytometry at baseline and after the 6-week intervention.
0-6 weeks
Change in white blood cell count before and after the 6-week intervention
Tidsram: 0-6 weeks
The white blood cell count will be measured using a hematology analyzer at baseline and after the 6-week intervention.
0-6 weeks
Change in monocyte count before and after the 6-week intervention
Tidsram: 0-6 weeks
The monocyte count will be measured using a hematology analyzer at baseline and after the 6-week intervention.
0-6 weeks
Change in neutrophil count before and after the 6-week intervention
Tidsram: 0-6 weeks
The neutrophil count will be measured using a hematology analyzer at baseline and after the 6-week intervention.
0-6 weeks
Change in eosinophil count before and after the 6-week intervention
Tidsram: 0-6 weeks
The eosinophil count will be measured using a hematology analyzer at baseline and after the 6-week intervention.
0-6 weeks
Change in plasma IL-6 before and after the 6-week intervention
Tidsram: 0-6 weeks
The plasma IL-6 concentration will be measured using a multiplex assay at baseline and after the 6-week intervention.
0-6 weeks
Change in plasma IL-10 before and after the 6-week intervention
Tidsram: 0-6 weeks
The plasma IL-10 concentration will be measured using a multiplex assay at baseline and after the 6-week intervention.
0-6 weeks
Change in plasma TNF-α before and after the 6-week intervention
Tidsram: 0-6 weeks
The plasma TNF-α concentration will be measured using a multiplex assay at baseline and after the 6-week intervention.
0-6 weeks
Change in 4-h LPS-induced TNF-α before and after the 6-week intervention
Tidsram: 0-6 weeks
The LPS-induced TNF-α concentration will be measured from whole-blood culture supernatant using an ELISA at baseline and after the 6-week intervention.
0-6 weeks
Change in 4-h LPS+IL-10-induced TNF-α before and after the 6-week intervention
Tidsram: 0-6 weeks
The LPS+IL10-induced TNF-α concentration will be measured from whole-blood culture supernatant using an ELISA at baseline and after the 6-week intervention.
0-6 weeks
Change in 24-h CD3/CD28 stimulated INF-γ before and after the 6-week intervention
Tidsram: 0-6 weeks
The CD3/CD28 stimulated INF-γ concentration will be measured from T-cell culture supernatant using an ELISA at baseline and after the 6-week intervention.
0-6 weeks
Change in PMA/Ionomysin induced INF-γ before and after the 6-week
Tidsram: 0-6 weeks
The PMA/Ionomysin induced INF-γ concentration will be measured from whole-blood culture supernatant using an ELISA at baseline and after the 6-week intervention.
0-6 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

11 februari 2026

Primärt slutförande (Beräknad)

31 december 2027

Avslutad studie (Beräknad)

31 december 2027

Studieregistreringsdatum

Först inskickad

23 juni 2026

Först inskickad som uppfyllde QC-kriterierna

23 juni 2026

Första postat (Faktisk)

30 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

30 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

23 juni 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera